OSI Pharmaceuticals Inc., regarding an article in the Jan. 22, 2004, edition of BioWorld Today, said that the pivotal trial expected to be used for OSI's Tarceva rolling NDA remains blinded. There has been no preliminary analysis.

 

Editor's note: The changes have been made in BioWorld Online.